A positive Aptima HPV result means the test detected active high-risk HPV in your cervical sample. Specifically, it found genetic material (mRNA) produced by 1 of 14 high-risk HPV types known to cause cervical cancer. This does not mean you have cancer or precancer. It means the virus is present and active, and your doctor will use this result alongside other information to decide on next steps.
What the Aptima Test Actually Detects
Most HPV tests look for the virus’s DNA, which tells you the virus is present in your cells. The Aptima test works differently. It looks for mRNA, a molecule the virus produces when it is actively making proteins called E6 and E7. These two proteins are the ones responsible for driving cells toward cancer over time. So while a DNA test tells you HPV is there, the Aptima test tells you HPV is there and doing something, specifically producing the proteins that matter most for cancer risk.
This distinction is clinically meaningful. Many HPV infections are dormant or on their way out. By targeting active viral behavior rather than mere presence, the Aptima test has higher specificity than traditional DNA-based HPV tests. In practical terms, it produces fewer false alarms. When the Aptima test is positive, it’s a stronger signal that the infection deserves attention.
Which HPV Types It Covers
The Aptima assay screens for 14 high-risk HPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. These are the strains most strongly linked to cervical cancer. The test does not distinguish between them on its own, so a positive result tells you that at least one of these 14 types is active but not which one. Your doctor may order a separate genotyping test to check specifically for types 16 and 18, which carry the highest risk.
What a Positive Result Does Not Mean
A positive Aptima result is not a cancer diagnosis. The majority of positive HPV test results do not indicate a high absolute risk of cancer. Even the more cancer-causing HPV types typically clear on their own without ever causing harm. Most HPV infections are transient. Your immune system will suppress or eliminate the virus in many cases, often within one to two years.
The test also cannot tell you when you were infected or who transmitted the virus. HPV can remain undetectable for years before showing up on a test, so a new positive result doesn’t necessarily mean a recent infection.
What Happens After a Positive Result
The next steps depend on the full picture: your Aptima result, your Pap test (cytology) result, and in some cases, which specific HPV type is involved.
- If your Pap test is normal and HPV is not type 16 or 18: The standard recommendation is to repeat testing in one year. Most of these infections resolve on their own, and a follow-up test will confirm whether the virus has cleared.
- If genotyping shows HPV 16 or 18: A colposcopy is typically recommended regardless of Pap results. These two types are responsible for roughly 70% of cervical cancers, so doctors take a closer look even when cells appear normal.
- If your Pap test is abnormal: Follow-up is guided by how abnormal the cells look, combined with your HPV status. This often means colposcopy, a procedure where a doctor examines your cervix under magnification and may take a small tissue sample (biopsy) to check for precancerous changes.
When primary HPV testing is used for screening, a Pap test is performed on all positive results to help determine next steps. In many labs, this happens automatically from the same sample you already provided, so you don’t need a second appointment.
Why mRNA Testing Reduces Unnecessary Worry
One of the challenges with HPV screening is that the virus is extremely common. Most sexually active people will have HPV at some point, and the vast majority of infections never progress to anything serious. Reacting too aggressively to every positive result can cause real harm: anxiety, unnecessary procedures, and in some cases, treatments that affect future pregnancies.
The Aptima test helps address this problem. Because it detects active viral protein production rather than just viral DNA sitting in cells, it filters out many infections that are inactive or already being cleared by the immune system. Studies comparing Aptima to DNA-based tests consistently show similar ability to catch true precancerous changes, with fewer positive results in people who turn out to be fine. That higher specificity means fewer colposcopies and biopsies for people who don’t need them.
How the Aptima Test Is Used in Screening
The FDA has approved the Aptima HPV assay for two main uses. First, it can be used in anyone 21 and older who has an unclear Pap result (called ASC-US) to help decide whether colposcopy is needed. Second, in people 30 and older, it can be used alongside a Pap test as part of routine cervical cancer screening, known as cotesting.
Your screening schedule after a positive result will follow risk-based guidelines that account for your age, HPV type, Pap results, and screening history. The goal is to monitor closely enough to catch precancerous changes early, while avoiding overtreatment of infections that will resolve. For most people with a positive HPV result and normal Pap, that means returning in 12 months rather than jumping straight to a procedure.